Halozyme Therapeutics (HALO) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Halozyme Therapeutics (HALO) over the last 14 years, with Q4 2025 value amounting to -$1.12.
- Halozyme Therapeutics' EPS (Weighted Average and Diluted) fell 20566.04% to -$1.12 in Q4 2025 from the same period last year, while for Dec 2025 it was $2.57, marking a year-over-year decrease of 2507.29%. This contributed to the annual value of $2.56 for FY2025, which is 2536.44% down from last year.
- As of Q4 2025, Halozyme Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.12, which was down 20566.04% from $1.43 recorded in Q3 2025.
- In the past 5 years, Halozyme Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of $1.48 in Q3 2021 and a low of -$1.12 during Q4 2025
- In the last 5 years, Halozyme Therapeutics' EPS (Weighted Average and Diluted) had a median value of $0.6 in 2023 and averaged $0.62.
- In the last 5 years, Halozyme Therapeutics' EPS (Weighted Average and Diluted) soared by 57500.0% in 2021 and then crashed by 20566.04% in 2025.
- Over the past 5 years, Halozyme Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at $0.46 in 2021, then dropped by 8.7% to $0.42 in 2022, then skyrocketed by 54.76% to $0.65 in 2023, then skyrocketed by 63.08% to $1.06 in 2024, then tumbled by 205.66% to -$1.12 in 2025.
- Its EPS (Weighted Average and Diluted) was -$1.12 in Q4 2025, compared to $1.43 in Q3 2025 and $1.33 in Q2 2025.